A second Alzheimer’s drug proven to slow cognitive decline was a step closer to US approval on Monday after clinical trial results published in a top journal confirmed its efficacy.
A second Alzheimer’s drug proven to slow cognitive decline was a step closer to US approval on Monday after clinical trial results published in a top journal confirmed its efficacy.